Bioregulator Peptides

Bioregulator peptides are a distinct class of very short peptides, typically two to four amino acids long, developed over five decades of research at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. The class began with peptide extracts isolated from animal organs (thymalin from the thymus, epithalamin from the pineal gland) and later expanded to include synthetic analogs of the active short-peptide fractions identified in those extracts, such as epithalon for the pineal extract and vilon, cortagen, and pinealon for other tissue preparations.

The central concept behind this class is the cytomedin hypothesis: that short peptides can enter cells, interact directly with DNA and histone proteins, and modulate gene expression in a tissue-specific manner. In this model, each organ produces or responds to particular short peptide sequences that help maintain protein synthesis rates in that tissue, and age-related decline in endogenous peptide availability contributes to reduced cellular function. Reported mechanisms across the class include epigenetic regulation of gene transcription, telomerase activation in the epithalon lineage, thymic support of T-cell differentiation in the thymalin lineage, and normalization of neuroendocrine and melatonin rhythms in the pineal lineage. Several of these peptides are registered as pharmaceutical drugs in Russia and some neighboring countries for age-related immune and neuroendocrine indications.

Readers should weigh one structural caveat with this category: nearly all published evidence traces back to a single research lineage, namely Khavinson's institute and its collaborators. Independent replication by unaffiliated laboratories is scarce, many studies are small or uncontrolled by Western regulatory standards, and a substantial share of the literature appears in Russian-language journals with limited international indexing. The reported effects are biologically coherent and internally consistent across decades of work, but the evidence base does not yet meet the independent-replication standard applied to peptides with multinational trial programs.